Top Stories
Regeneron Otarmeni approval marks first FDA-cleared gene therapy for genetic hearing loss with a zero-price commercial strategy
On April 23, 2026, the FDA granted accelerated approval to Otarmeni (lunsotogene parvec-cwha) for severe-to-profound and profound OTOF-related hearing loss, making it the first gene therapy cleared for any form of inherited hearing impairment, according to Regeneron Pharmaceuticals investor relations. The accelerated approval is based on improvement of hearing sensitivity by average pure tone audiometry at week 24, with continued approval contingent upon verification of clinical benefit in the confirmatory portion of the CHORD trial. In pivotal data, 80% of participants met or surpassed the primary hearing endpoint, and with extended follow-up to 48 weeks, 42% achieved normal hearing inclusive of whispered speech detection. OTOF-related hearing loss affects an estimated 5,000 to 10,000 individuals in the US, according to Regeneron, representing one of the smaller addressable populations for an approved gene therapy to date. Notably, Regeneron announced it will provide Otarmeni at no charge in the US, a departure from the $1M-plus pricing seen across other one-time gene therapies. As Endpoints News reported, this positions Regeneron to capture patient access without triggering payer resistance, though it raises open questions about how the company recovers development costs and whether the free-access model is sustainable or sets a precedent for other sponsors. Manufacturing scalability and long-term durability data beyond the CHORD follow-up window remain key variables to watch.
AstraZeneca Ultomiris Phase 3 IgAN data supports fifth rare disease indication filing with complement inhibitor franchise expanding
AstraZeneca reported that Ultomiris (ravulizumab) delivered a clinically meaningful and statistically significant reduction in urine protein levels after 34 weeks in a Phase 3 trial for IgA nephropathy (IgAN), a rare immune-complex kidney disease affecting an estimated 130,000 diagnosed patients in the US according to published epidemiologic data, as reported by Fierce Pharma. This would represent the fifth approved rare disease indication for Ultomiris, which already covers paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disorder. The IgAN result extends complement C5 inhibition into a kidney disease space where Calliditas Therapeutics (Tarpeyo) and Novartis (Fabhalta, a factor B inhibitor) have established early footholds through different mechanistic approaches. Proteinuria reduction at 34 weeks is a recognized surrogate endpoint, but longer-term data on GFR preservation and renal survival will be critical for both regulatory submission and payer acceptance. AstraZeneca has not yet announced a BLA submission timeline. The data positions Ultomiris to compete in IgAN on the strength of an established complement inhibitor safety profile, though differentiation from oral and subcutaneous alternatives will be a market access consideration.
Sarepta Q1 2026 earnings scheduled as ELEVIDYS commercial trajectory and payer contracting remain key investor focus points
Sarepta Therapeutics announced it will report first quarter 2026 financial results on May 6, 2026, according to the company's investor relations release. The earnings call is expected to provide updated commercial figures for ELEVIDYS (delandistrogene moxeparvovec), the Duchenne muscular dystrophy gene therapy that received accelerated approval in June 2023 and traditional approval expansion in June 2024. Key metrics to watch include net product revenue per quarter, the number of patients dosed, and any updated guidance on outcomes-based contracting arrangements with payers. ELEVIDYS carries a list price of approximately $3.2 million per dose based on Sarepta's announced pricing, and payer acceptance has been a central variable in determining commercial uptake across the estimated 10,000 to 12,000 Duchenne patients in the US who may be eligible, according to company estimates. Manufacturing lot consistency and vector yield have also been cited by analysts as potential constraints on patient throughput. Sarepta investor relations noted the report date but did not disclose preliminary figures. The Q1 update will also arrive against the backdrop of ongoing long-term follow-up data from the EMBARK trial, which continues to be the primary durability evidence base supporting the therapy's full approval label.
Ionis zilganersen stabilizes gait in ultra-rare Alexander disease as NDA receives FDA priority review with September 2026 PDUFA date
Ionis Pharmaceuticals reported that zilganersen, an antisense oligonucleotide targeting GFAP mRNA, demonstrated statistically significant stabilization of gait speed in a pivotal study in Alexander disease (AxD), as reported by BioSpace. The primary endpoint — gait speed on the 10-Meter Walk Test at week 61 — showed a least squares mean difference of 33.3% versus control (p=0.0412), with favorable safety and tolerability. Results across key secondary and exploratory endpoints evaluating adaptive function, communication, gastrointestinal symptoms, sleep, and seizures also consistently favored zilganersen. Alexander disease is a rare, progressive, and often fatal neurological disease caused by mutations in the GFAP gene that affects astrocytes in the brain, occurring in approximately 1 per 1 to 3 million people worldwide, according to Ionis investor relations. There are no approved disease-modifying treatments. The FDA has accepted the NDA for priority review with a PDUFA target action date of September 22, 2026. Zilganersen also holds Breakthrough Therapy designation. If approved, it would be the first treatment for Alexander disease.
Pipeline Watch
A pilot study of sail-assisted telerehabilitation in rare bone disorders, sponsored by Istituto Ortopedico Rizzoli, has reached completed status per ClinicalTrials.gov. The small-scale feasibility study (NCT07102875) explored remote rehabilitation delivery for patients with rare skeletal conditions, a population with historically limited access to specialized physical therapy. Full results have not yet been posted.
Competitive Landscape
Otarmeni approved at no US list charge contrasts with gene therapies priced between $1M and $3.5M based on publicly announced pricing for conditions with comparable or smaller patient populations. The approach eliminates payer negotiation friction but raises questions about cost recovery and whether CMS or commercial payers will be asked to cover administration and surgical delivery costs, which may be substantial for intracochlear delivery.
| Therapy | Indication | Approval Status | US List Price (Announced) |
|---|---|---|---|
| Otarmeni (Regeneron) | OTOF hearing loss | FDA Accelerated Approval 2026 | No charge |
| ELEVIDYS (Sarepta) | Duchenne MD | FDA Approved 2024 | $3.2M |
| Zolgensma (Novartis) | SMA Type 1 | FDA Approved 2019 | $2.1M |
| Hemgenix (CSL Behring) | Hemophilia B | FDA Approved 2022 | $3.5M |
AstraZeneca enters the IgAN therapy space via complement C5 inhibition as Calliditas Therapeutics holds an approved SGLT2-combined corticosteroid (Tarpeyo) and Novartis advances Fabhalta (iptacopan), a factor B inhibitor with a different complement pathway target. Mechanistic differentiation, route of administration, and long-term GFR data will shape payer and nephrologist preference.
| Company | Agent | Mechanism | IgAN Status |
|---|---|---|---|
| AstraZeneca | Ultomiris (ravulizumab) | C5 complement inhibitor | Phase 3 data (filing TBD) |
| Calliditas | Tarpeyo (budesonide) | Targeted-release corticosteroid | FDA Approved |
| Novartis | Fabhalta (iptacopan) | Factor B complement inhibitor | FDA Accelerated Approval Aug 2024 (IgAN) |
Otarmeni regulatory clearance validates intracochlear AAV delivery as a viable route for genetic hearing restoration. Programs targeting GJB2 (connexin 26) mutations, which account for a larger proportion of congenital deafness cases than OTOF, may reference the CHORD trial design and FDA review framework as they advance through clinical stages.
Forward Looking
- Sarepta Q1 2026 earnings on May 6, 2026 will reveal whether ELEVIDYS quarterly net revenue is accelerating or plateauing, with payer coverage breadth and EMBARK durability data serving as the primary commercial catalysts for the remainder of 2026.
- AstraZeneca BLA submission timing for Ultomiris in IgAN is the next regulatory catalyst to monitor; the agency's position on proteinuria as a standalone surrogate versus required GFR data will set the filing bar.
- Regeneron zero-price Otarmeni model raises a structural question for the field: whether administrative, surgical, and follow-up costs borne by hospital systems will require separate payer negotiations that effectively set an indirect price floor.
- Expanded CHORD trial follow-up disclosures for Otarmeni, including durability of normal hearing beyond initial response windows, will be central to confirmatory evidence supporting continued accelerated approval and any future reimbursement discussions outside the US.
- The FDA's PDUFA target action date for Ionis zilganersen in Alexander disease is September 22, 2026; if approved, it would be the first disease-modifying treatment for this ultra-rare neurological condition.